203 related articles for article (PubMed ID: 1355531)
1. Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms.
Barbareschi M; Girlando S; Mauri FA; Arrigoni G; Laurino L; Dalla Palma P; Doglioni C
J Pathol; 1992 Apr; 166(4):343-50. PubMed ID: 1355531
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.
Brambilla E; Negoescu A; Gazzeri S; Lantuejoul S; Moro D; Brambilla C; Coll JL
Am J Pathol; 1996 Dec; 149(6):1941-52. PubMed ID: 8952529
[TBL] [Abstract][Full Text] [Related]
3. Molecular markers help characterize neuroendocrine lung tumors.
Rusch VW; Klimstra DS; Venkatraman ES
Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
[TBL] [Abstract][Full Text] [Related]
4. Typical and atypical carcinoids within the pulmonary APUD tumor spectrum.
DeCaro LF; Paladugu R; Benfield JR; Lovisatti L; Pak H; Teplitz RL
J Thorac Cardiovasc Surg; 1983 Oct; 86(4):528-36. PubMed ID: 6621081
[TBL] [Abstract][Full Text] [Related]
5. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
6. Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53.
Wang DG; Johnston CF; Sloan JM; Buchanan KD
J Pathol; 1998 Mar; 184(3):247-51. PubMed ID: 9614375
[TBL] [Abstract][Full Text] [Related]
7. Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours.
Kasprzak A; Olejniczak K; Przybyszewska W; Zabel M
Folia Morphol (Warsz); 2007 Aug; 66(3):159-66. PubMed ID: 17985312
[TBL] [Abstract][Full Text] [Related]
8. Abnormal p53 expression in lung neuroendocrine tumors. Diagnostic and prognostic implications.
Roncalli M; Doglioni C; Springall DR; Papotti M; Pagani A; Polak JM; Ibrahim NB; Coggi G; Viale G
Diagn Mol Pathol; 1992 Jun; 1(2):129-35. PubMed ID: 1364172
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung.
Coppola D; Clarke M; Landreneau R; Weyant RJ; Cooper D; Yousem SA
Mod Pathol; 1996 May; 9(5):484-90. PubMed ID: 8733762
[TBL] [Abstract][Full Text] [Related]
10. LKB1 protein expression in neuroendocrine tumors of the lung.
Amin RM; Hiroshima K; Iyoda A; Hoshi K; Honma K; Kuroki M; Kokubo T; Fujisawa T; Miyagi Y; Nakatani Y
Pathol Int; 2008 Feb; 58(2):84-8. PubMed ID: 18199157
[TBL] [Abstract][Full Text] [Related]
11. Infrequent mutations of the p53 gene in pulmonary carcinoid tumors.
Lohmann DR; Fesseler B; Pütz B; Reich U; Böhm J; Präuer H; Wünsch PH; Höfler H
Cancer Res; 1993 Dec; 53(23):5797-801. PubMed ID: 8242638
[TBL] [Abstract][Full Text] [Related]
12. Divergent differentiation in neuroendocrine lung tumors.
Brambilla E; Lantuejoul S; Sturm N
Semin Diagn Pathol; 2000 May; 17(2):138-48. PubMed ID: 10839614
[TBL] [Abstract][Full Text] [Related]
13. Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas.
Gugger M; Burckhardt E; Kappeler A; Hirsiger H; Laissue JA; Mazzucchelli L
J Pathol; 2002 Apr; 196(4):408-15. PubMed ID: 11920736
[TBL] [Abstract][Full Text] [Related]
14. The expression of selected neuroendocrine markers and of anti-neoplastic cytokines (IL-2 and IL-12) in lung cancers.
Kasprzak A; Przewoźna M; Surdyk-Zasada J; Zabel M
Folia Morphol (Warsz); 2003 Nov; 62(4):497-9. PubMed ID: 14655151
[TBL] [Abstract][Full Text] [Related]
15. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins.
Sharma M; Ralte A; Arora R; Santosh V; Shankar SK; Sarkar C
Pathology; 2004 Apr; 36(2):139-44. PubMed ID: 15203749
[TBL] [Abstract][Full Text] [Related]
16. Expression of p64c-myc and neuroendocrine properties define three subclasses of small cell lung cancer.
Bepler G; Bading H; Heimann B; Kiefer P; Havemann K; Moelling K
Oncogene; 1989 Jan; 4(1):45-50. PubMed ID: 2536917
[TBL] [Abstract][Full Text] [Related]
17. Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
Van Eeden S; Quaedvlieg PF; Taal BG; Offerhaus GJ; Lamers CB; Van Velthuysen ML
Hum Pathol; 2002 Nov; 33(11):1126-32. PubMed ID: 12454818
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of neural-cadherin in pulmonary epithelial tumours.
Zynger DL; Dimov ND; Ho LC; Laskin WB; Yeldandi AV
Histopathology; 2008 Feb; 52(3):348-54. PubMed ID: 18269586
[TBL] [Abstract][Full Text] [Related]
19. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of neuroendocrine carcinoma and carcinoid tumor with special reference to expression of HLA-DR antigen and PCNA.
Kimura N; Nagura H
Zentralbl Pathol; 1993 Jun; 139(2):171-5. PubMed ID: 7690246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
